2.7.1.33: pantothenate kinase
This is an abbreviated version!
For detailed information about pantothenate kinase, go to the full flat file.
Word Map on EC 2.7.1.33
-
2.7.1.33
-
neurodegeneration
-
kinase-associated
-
panks
-
sign
-
dystonia
-
ganglia
-
hallervorden-spatz
-
extrapyramidal
-
parkinsonism
-
eye-of-the-tiger
-
pla2g6
-
phosphopantothenate
-
dysarthria
-
tiger
-
neuroaxonal
-
phosphopantetheine
-
hypointensity
-
medicine
-
4'-phosphopantothenate
-
pigmentary
-
pantothenamide
-
bradykinesia
-
synthesis
-
atp13a2
-
4'-phosphopantetheine
-
pantethine
-
drug development
-
neuroferritinopathy
-
choreoathetosis
-
phosphopantothenoylcysteine
- 2.7.1.33
- neurodegeneration
-
kinase-associated
-
panks
- sign
- dystonia
- ganglia
- hallervorden-spatz
-
extrapyramidal
- parkinsonism
-
eye-of-the-tiger
- pla2g6
- phosphopantothenate
- dysarthria
- tiger
-
neuroaxonal
- phosphopantetheine
-
hypointensity
- medicine
- 4'-phosphopantothenate
-
pigmentary
- pantothenamide
-
bradykinesia
- synthesis
-
atp13a2
- 4'-phosphopantetheine
- pantethine
- drug development
-
neuroferritinopathy
-
choreoathetosis
-
phosphopantothenoylcysteine
Reaction
Synonyms
4-phosphopantoate, BaPanK, Cab1, Cab1p, CoaA, coaW, CoaX, D-pantothenate kinase, EhPAnK, fumble, hPanK, hPanK1, hPANK2, hPanK3, hPanK4, HpPanK-III, HsPANK3, HsPANK4, kinase, pantothenate (phosphorylating), More, mPank, mPank1, mPanK2, mPanK3, MtCoaA, MtPanK, PAK, PanK, PanK-III, PanK1, PanK1alpha, PanK1b, PanK2, PanK3, PanK4, PanKBa, pantothenate kinase, pantothenate kinase 1, pantothenate kinase 2, pantothenate kinase 3, pantothenate kinase 4, pantothenate kinase-2, pantothenic acid kinase, PfPanK, Pfpank1, PoK, rPanK4, Rts protein
ECTree
2.7.1.33 pantothenate kinaseAdvanced search results
results (
results (Inhibitors
Inhibitors on EC 2.7.1.33 - pantothenate kinase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
(2E)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoic acid
-
(2R)-2,4-dihydroxy-3,3-dimethylbutanohydrazide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
(2R)-2,4-dihydroxy-N-(2-hydroxyethyl)-3,3-dimethylbutanamide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
(2R)-N-(2,3-dihydroxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
(2Z)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoic acid
-
(2Z)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoic acid
-
1,4-dioxa-8-azaspiro[4.5]dec-8-yl[2-[(3-fluorophenyl)sulfanyl]pyridin-4-yl]methanone
-
mixed non-competitive inhibition
2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide
2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide
2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
2,6-difluoro-N-[1-(5-[[2-(4-fluorophenoxy)ethyl]sulfanyl]-4-methyl-4H-1,2,4-triazol-3-yl)ethyl]benzamide
competitive inhibition
2-chloro-N-[1-(5-[[2-(4-fluorophenoxy)ethyl]sulfanyl]-4-methyl-4H-1,2,4-triazol-3-yl)ethyl]benzamide
competitive inhibition
2-[(4'-cyano-2-[[4-(pyridin-2-yl)piperazin-1-yl]methyl][1,1'-biphenyl]-4-yl)oxy]-1-oxoethan-1-aminide
non-competitive inhibition
2-[2-(1-benzoylpiperidin-4-yl)-5-methyl-1,3-thiazol-4-yl]-N-(4-methylphenyl)acetamide
-
uncompetitive inhibition
4-(2,4-dihydroxy-3,3-dimethylbutylamido)butyric acid
-
competitive inhibitor; competitive inhibitor, IC50: 0.05-0.15 mM
5'-deoxy-5'-(4-(beta-D-galactopyranosyloxymethyl)-1,2,3-triazol-1-yl)adenosine
-
competitive inhibitor with respect to ATP
benzyl (2E)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
benzyl (2E)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
benzyl (2Z)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
benzyl (2Z)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
CoA esters
-
feedback inhibition, inhibition kinetics of recombinant isozyme mPanK2
dehydroisoandrosterone
about 30% residual activity at 0.1 mM (isoform PanK3)
Dehydroisoandrosterone sulfate
about 8% residual activity at 0.1 mM (isoform PanK3)
ethyl (2E)-2-methyl-3-[[(4R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl]amino]prop-2-enoate
-
ethyl (2E)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]-2-methylprop-2-enoate
-
ethyl (2E)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
ethyl (2E)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
ethyl (2E)-3-[[(4R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl]amino]prop-2-enoate
-
ethyl (2Z)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
ethyl (2Z)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
malonyl CoA
competitive versus ATP, uncompetitive versus pantothenate
MCC-555
MCC-555 inhibits all three isoforms with a rank order of PanK3 > PanK2 > PanK1b; MCC-555 inhibits all three isoforms with a rank order of PanK3 > PanK2 > PanK1b
methyl (2E)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
methyl (2E)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
methyl (2Z)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
methyl (2Z)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
N-(1-[5-[(4-fluorobenzyl)sulfanyl]-4-methyl-4H-1,2,4-triazol-3-yl]ethyl)-2-(trifluoromethyl)benzamide
competitive inhibition
N-[1-(5-[[2-(4-chlorophenoxy)ethyl]sulfanyl]-4-methyl-4H-1,2,4-triazol-3-yl)ethyl]naphthalene-1-carboxamide
-
competitive inhibition
N-[1-(5-[[2-(4-fluorophenoxy)ethyl]sulfanyl]-4-methyl-4H-1,2,4-triazol-3-yl)ethyl]-2-(trifluoromethyl)benzamide
competitive inhibition
N-[1-(5-[[2-(4-fluorophenoxy)ethyl]sulfanyl]-4-[(4-fluorophenyl)methyl]-4H-1,2,4-triazol-3-yl)ethyl]-2-(trifluoromethyl)benzamide
competitive inhibition
pregnenolone sulfate
about 10% residual activity at 0.1 mM (isoform PanK3); about 92% residual activity at 0.1 mM (isoform PanK3)
tert-butyl (2E)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
tert-butyl (2E)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
tert-butyl (2Z)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
tert-butyl (2Z)-3-[[(2S)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoate
-
[(4'-cyano-2-[[4-(pyridin-2-yl)piperazin-1-yl]methyl][1,1'-biphenyl]-4-yl)oxy]acetic acid
non-competitive inhibition
[2-[(3-chlorophenyl)sulfanyl]pyridin-4-yl][4-(hydroxymethyl)piperidin-1-yl]methanone
-
mixed non-competitive inhibition
[2-[(3-chlorophenyl)sulfanyl]quinolin-4-yl](piperidin-1-yl)methanone
-
mixed non-competitive inhibition
[[2-[[4-(6-methylpyridin-2-yl)piperazin-1-yl]methyl]-4'-(trifluoromethoxy)biphenyl-4-yl]oxy]acetic acid
-
mixed non-competitive inhibition
(2E)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoic acid
CJ-15,801, an enamide analogue of pantothenate isolated from the fungus Seimatosporium sp. CL28611. CJ-15,801 is phosphorylated by pantothenate kinase (PanK). Subsequently, phospho-CJ-15,801 is accepted as a substrate by the next enzyme in the pathway (phosphopantothenoylcysteine synthetase, PPCS), and reacts to become cytidylylated. The cytidylylated phospho-CJ-15,801, which closely mimics the natural reaction intermediate and binds tightly and reversibly to the enzyme, does not react further and instead inhibits the enzyme
(2E)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoic acid
-
(2R)-2,4-dihydroxy-3,3-dimethyl-N'-phenylbutanohydrazide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
(2R)-2,4-dihydroxy-3,3-dimethyl-N'-phenylbutanohydrazide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
(2R)-N-allyl-2,4-dihydroxy-3,3-dimethylbutanamide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
(2R)-N-allyl-2,4-dihydroxy-3,3-dimethylbutanamide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
(R)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid
-
80.6% inhibition at 0.1 mM, purified enzyme
(R)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid
-
29.4% inhibition at 0.1 mM, purified enzyme
(R)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid
-
2.7% inhibition at 0.1 mM, cell extract
(R)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid
-
78.7% inhibition at 0.1 mM, purified enzyme
(R)-4-(2-amino-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid
-
11% inhibition at 0.1 mM, purified enzyme
(R)-4-(2-amino-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid
-
13.1% inhibition at 0.1 mM, cell extract
(S)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid
-
12.5% inhibition at 0.1 mM, purified enzyme
(S)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid
-
54.6% inhibition at 0.1 mM, purified enzyme
(S)-trifluoro-methanesulfonic acid 4,4-dimethyl-2-oxo-tetrahydro-furan-3-yl-ester
-
-
(S)-trifluoro-methanesulfonic acid 4,4-dimethyl-2-oxo-tetrahydro-furan-3-yl-ester
-
-
2,4-dihydroxy-3,3-dimethyl N-(2-heptylcarbamoyl-ethyl)-butyramide
-
10.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-heptylcarbamoyl-ethyl)-butyramide
-
76.4% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-heptylcarbamoyl-ethyl)-butyramide
-
89.6% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-(2-heptylcarbamoyl-ethyl)-butyramide
-
98.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-isobutylcarbamoyl-ethyl)-butyramide
-
46.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-isobutylcarbamoyl-ethyl)-butyramide
-
71.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-isobutylcarbamoyl-ethyl)-butyramide
-
89.9% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-(2-isobutylcarbamoyl-ethyl)-butyramide
-
97.1% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide
-
12.6% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide
-
72.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide
-
81.4% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide
-
98.8% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-phenethylcarbamoyl-ethyl)-butyramide
-
59.5% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-phenethylcarbamoyl-ethyl)-butyramide
-
57.8% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-phenethylcarbamoyl-ethyl)-butyramide
-
80.9% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-(2-phenethylcarbamoyl-ethyl)-butyramide
-
89.5% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide
-
51.4% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide
-
82.5% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide
-
86.8% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide
-
99.1% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-[1-methyl-3-phenyl-propylcarbamoyl]-ethyl)-butyramide
-
40.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-[1-methyl-3-phenyl-propylcarbamoyl]-ethyl)-butyramide
-
71.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-[1-methyl-3-phenyl-propylcarbamoyl]-ethyl)-butyramide
-
84.6% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-(2-[1-methyl-3-phenyl-propylcarbamoyl]-ethyl)-butyramide
-
86.4% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide
-
35.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide
-
44.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide
-
70.5% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide
-
17.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-[3,4,5-trimethoxy-benzylcarbamoyl]-ethyl)-butyramide
-
28.4% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-[3,4,5-trimethoxy-benzylcarbamoyl]-ethyl)-butyramide
-
33.4% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-(2-[3,4,5-trimethoxy-benzylcarbamoyl]-ethyl)-butyramide
-
57.4% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-(2-[3,4,5-trimethoxy-benzylcarbamoyl]-ethyl)-butyramide
-
8.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide
-
71.9% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide
-
3.0% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide
-
93.3% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide
-
76.6% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethoxy-ethylcarbamoyl)-ethyl]-butyramide
-
41.8% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethoxy-ethylcarbamoyl)-ethyl]-butyramide
-
28.6% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethoxy-ethylcarbamoyl)-ethyl]-butyramide
-
68.9% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethoxy-ethylcarbamoyl)-ethyl]-butyramide
-
95.1% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethylsulfanylethylcarbamoyl)-ethyl]-butyramide
-
61.0% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethylsulfanylethylcarbamoyl)-ethyl]-butyramide
-
53.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethylsulfanylethylcarbamoyl)-ethyl]-butyramide
-
82.9% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethylsulfanylethylcarbamoyl)-ethyl]-butyramide
-
97.6% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-methylsulfanylethylcarbamoyl)-ethyl]-butyramide
-
49.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-methylsulfanylethylcarbamoyl)-ethyl]-butyramide
-
61.9% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-methylsulfanylethylcarbamoyl)-ethyl]-butyramide
-
85.0% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[2-(2-methylsulfanylethylcarbamoyl)-ethyl]-butyramide
-
96.5% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-butyramide
-
13.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-butyramide
-
10.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-butyramide
-
39.1% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-butyramide
-
4.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(3,7-dimethylocta-2,6-dienylcarbamoyl)-ethyl]-butyramide
-
92.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(3,7-dimethylocta-2,6-dienylcarbamoyl)-ethyl]-butyramide
-
90.6% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(3,7-dimethylocta-2,6-dienylcarbamoyl)-ethyl]-butyramide
-
98.9% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[2-(3,7-dimethylocta-2,6-dienylcarbamoyl)-ethyl]-butyramide
-
97.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide
-
62.1% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide
-
32.3% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide
-
61.2% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide
-
96.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide
-
72.6% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide
-
54.3% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide
-
87.2% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide
-
97.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
54.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
55.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
82.2% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
53.9% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[3-(4-benzyl-piperazin-1-yl)-3-oxo-propyl]-butyramide
-
15.9% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[3-(4-benzyl-piperazin-1-yl)-3-oxo-propyl]-butyramide
-
7.3% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-3,3-dimethyl N-[3-(4-benzyl-piperazin-1-yl)-3-oxo-propyl]-butyramide
-
73.0% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-3,3-dimethyl N-[3-(4-benzyl-piperazin-1-yl)-3-oxo-propyl]-butyramide
-
9.3% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(2-hydroxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
25.9% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(2-hydroxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
3.4% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(2-hydroxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
56.7% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-N-[2-(2-hydroxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
72.2% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(2-methoxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
26.8% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(2-methoxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
28.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(2-methoxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
67.6% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-N-[2-(2-methoxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
90.1% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(3-hydroxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
i.e. pantothenol, 36.7% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(3-hydroxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
i.e. pantothenol, 11.5% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(3-hydroxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
i.e. pantothenol, 70.3% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-N-[2-(3-hydroxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
i.e. pantothenol, 79.9% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
52.9% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
38.6% inhibition at 0.1 mM, purified enzyme
2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
64.9% inhibition at 0.1 mM, cell extract
2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
competitive, pantothenic acid analogue with 2,4-dihydroxy-3,3-dimethylbutyramide core of pantothenate, inhibition mechanism
2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide
-
94.4% inhibition at 0.1 mM, purified enzyme
acetyl-CoA
competitive inhibitor of purified PanK2 with respect to ATP; IC50: 60 nM, competitive inhibitor with respect to ATP
acetyl-CoA
feedback inhibition, competitive versus ATP, but acetyl-CoA binds far more tightly than ATP. The 1alpha and 1beta isoforms are least sensitive to inhibition, whereas isoforms 2 and 3 are more potently inhibited by acetyl-CoA; feedback inhibition, competitive versus ATP, but acetyl-CoA binds far more tightly than ATP. The 1alpha and 1beta isoforms are least sensitive to inhibition, whereas isoforms 2 and 3 are more potently inhibited by acetyl-CoA; feedback inhibition, competitive versus ATP, but acetyl-CoA binds far more tightly than ATP. The 1alpha and 1beta isoforms are least sensitive to inhibition, whereas isoforms 2 and 3 are more potently inhibited by acetyl-CoA
acetyl-CoA
-
feedback inhibition, regulatory function, isozyme PanK1beta and isozyme PanK3, strong inhibition of mutant chimera PanK1beta-3-1beta, slight inhibition of mutant chimera PanK3-1beta-3
acetyl-CoA
feedback inhibition, competitive versus ATP, but acetyl-CoA binds far more tightly than ATP. The 1alpha and 1beta isoforms are least sensitive to inhibition, whereas isoforms 2 and 3 are more potently inhibited by acetyl-CoA; feedback inhibition, competitive versus ATP, but acetyl-CoA binds far more tightly than ATP. The 1alpha and 1beta isoforms are least sensitive to inhibition, whereas isoforms 2 and 3 are more potently inhibited by acetyl-CoA; feedback inhibition, competitive versus ATP, but acetyl-CoA binds far more tightly than ATP. The 1alpha and 1beta isoforms are least sensitive to inhibition, whereas isoforms 2 and 3 are more potently inhibited by acetyl-CoA. Comparison of the overall structures of the actyl-CoA-bound inactive and the active PANK3 conformations, overview
Acyl carrier protein
-
PAK II: inhibition, PAK I: stimulation between 0.015-0.035 mM
acyl-CoA-esters
long chain acyl CoA, feed-back inhibition, isoform PanK1alpha
acyl-CoA-esters
-
long-chain acyl-CoAs less efficient than short-chain ester
ADP
competitive inhibitor of isoform PanK3 with respect to ATP1 and a mixed-type inhibitor with respect to pantothenate
CoA
feedback inhibition, Tm values of wild-type and its mutants and dissociation constants of CoA, overview
CoA
-
not reversible by D-carnitine, acetyl-L-carnitine or other carnitine analogs; reversible by L-carnitine
coenzyme A
-
feedback inhibition, regulatory function, isozyme PanK1beta, slight inhibition of isozyme PanK3
coenzyme A
-
feedback inhibition regulates pantothenol uptake. Furosemide reduces this inherent feedback inhibition by competing with coenzyme A for binding to pantothenate kinase, thereby increasing pantothenol uptake
malonyl-CoA
-
feedback inhibition, regulatory function, isozyme PanK3, slight inhibition of isozyme PanK1beta
N-heptylpantothenamide
-
IC50 is 0.0048 mM, potent growth inhibitory anti-metabolite
N-pentylpantothenamide
-
IC50 is 0.0035 mM, has antimicrobial activity against Staphylococcus aureus
palmitoyl-CoA
-
feedback inhibition, regulatory function, isozyme PanK3, mutant chimera PanK1beta-3-1beta, slight inhibition of mutant chimera PanK3-1beta-3
additional information
-
no inhibition by (R)-4-(2-amino-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid and (S)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid, structural features required for enzyme inhibition, overview
-
additional information
-
the enzyme is not subject to feedback inhibition by CoASH
-
additional information
the enzyme is not subject to feedback inhibition by CoASH
-
additional information
-
no inhibition by N-pentylpantothenamide, enzyme is not affected by CoA or acetyl-CoA
-
additional information
-
no inhibition by 2,2'-dipyridyl, Ca2+, Cd2+, 3'-AMP, GTP, GDP, ITP, UTP; not inhibitory: 3',5'-ADP
-
additional information
inhibitor library screening and evaluation of cytotoxicity against human fibroblast MRC-5 cells. IC50 values for cytotoxicity against Entamoeba trophozoites and human MRC-5 cells, overview
-
additional information
-
inhibitor library screening and evaluation of cytotoxicity against human fibroblast MRC-5 cells. IC50 values for cytotoxicity against Entamoeba trophozoites and human MRC-5 cells, overview
-
additional information
-
not inhibitory: 3',5'-ADP; not inhibitory: cAMP, NADH, NADPH, CoA:glutathione disulfide; not inhibitory: NAD+
-
additional information
-
structural features required for enzyme inhibition, overview
-
additional information
no inhibition by N-pentylpantothenamide, enzyme is not affected by CoA or acetyl-CoA
-
additional information
-
no inhibition by N-pentylpantothenamide, enzyme is not affected by CoA or acetyl-CoA
-
additional information
-
no inhibition by (S)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid, structural features required for enzyme inhibition, overview
-
additional information
-
in vivo antiplasmodial activities of the inhibitor molecules, overview
-
additional information
structure-activity analysis of (2E)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoic acid (CJ-15,801) analogues that interact with Plasmodium falciparum pantothenate kinase and inhibit parasite proliferation. Inhibitor selectivity, overview. The enamide analogues of pantothenate may inhibit pantothenate phosphorylation by one of two mechanisms: (i) by directly inhibiting PfPanK, or (ii) by serving as alternate substrates that are competitively phosphorylated. It is noteworthy that the IC50 value of the best pantothenate phosphorylation inhibitor is 13fold lower than the pantothenate concentration present in the assay (0.0018 mM). Assuming competition for the same binding site, this is consistent with the enamide binding PanK with higher affinity and/or being turned over more slowly than the natural substrate. Effect of pantothenate supplementation on the antiplasmodial activity of CJ-15,801 and derivatives
-
additional information
-
structure-activity analysis of (2E)-3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]prop-2-enoic acid (CJ-15,801) analogues that interact with Plasmodium falciparum pantothenate kinase and inhibit parasite proliferation. Inhibitor selectivity, overview. The enamide analogues of pantothenate may inhibit pantothenate phosphorylation by one of two mechanisms: (i) by directly inhibiting PfPanK, or (ii) by serving as alternate substrates that are competitively phosphorylated. It is noteworthy that the IC50 value of the best pantothenate phosphorylation inhibitor is 13fold lower than the pantothenate concentration present in the assay (0.0018 mM). Assuming competition for the same binding site, this is consistent with the enamide binding PanK with higher affinity and/or being turned over more slowly than the natural substrate. Effect of pantothenate supplementation on the antiplasmodial activity of CJ-15,801 and derivatives
-
additional information
-
not inhibitory: Mg2+, NADP+; not inhibitory: NAD+
-
additional information
-
not inhibitory: 3',5'-ADP; not inhibitory: CoASH, acetyl-CoA
-
additional information
-
no inhibition by (R)-4-(2-amino-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid, structural features required for enzyme inhibition, overview
-
additional information
A0A167Z3Z6
the potent antistaphylococcal activity of N-substituted pantothenamides (PanAms) exhibit inhibition of Staphylococcus aureus atypical type II pantothenate kinase (SaPanKII). The PanAms are phosphorylated by SaPanKII but remain bound at the active site. This occurs primarily through interactions with Tyr240' and Thr172'. Kinetic analysis shows a strong correlation between kcat (slow PanAm turnover) and IC50 (inhibition of pantothenate phosphorylation) values, suggesting that SaPanKII inhibition occurs via a delay in product release. The two PanAms, N-(benzo[d][1,3]dioxol-5-ylmethyl)pantothenamide and N-(5-methoxypentyl)pantothenamide, effectively combine both hydrogen bonding and hydrophobic interactions, resulting in the most potent SaPanKII inhibition described to date. Design and synthesis of a series of N-substituted pantothenamides, analysis of the PanAm binding mode and interaction with the N-substituent binding site, structure-activity realtionships, MIC values, overview
-
additional information
-
the potent antistaphylococcal activity of N-substituted pantothenamides (PanAms) exhibit inhibition of Staphylococcus aureus atypical type II pantothenate kinase (SaPanKII). The PanAms are phosphorylated by SaPanKII but remain bound at the active site. This occurs primarily through interactions with Tyr240' and Thr172'. Kinetic analysis shows a strong correlation between kcat (slow PanAm turnover) and IC50 (inhibition of pantothenate phosphorylation) values, suggesting that SaPanKII inhibition occurs via a delay in product release. The two PanAms, N-(benzo[d][1,3]dioxol-5-ylmethyl)pantothenamide and N-(5-methoxypentyl)pantothenamide, effectively combine both hydrogen bonding and hydrophobic interactions, resulting in the most potent SaPanKII inhibition described to date. Design and synthesis of a series of N-substituted pantothenamides, analysis of the PanAm binding mode and interaction with the N-substituent binding site, structure-activity realtionships, MIC values, overview
-
additional information
feedback inhibition by CoA/acetyl-CoA and product inhibition by 4'-phosphopantothenate are not observed
-
additional information
-
feedback inhibition by CoA/acetyl-CoA and product inhibition by 4'-phosphopantothenate are not observed
-
